Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTS2190
- Development stage
- Phase 2
- Lead developer
- Cytosinlab Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CTS2190 is an orally administered small molecule inhibitor targeting protein arginine N-methyltransferase 1 (PRMT1), developed by Cytosinlab Pharmaceutical Technology. PRMT1 is an enzyme involved in the methylation of arginine residues on histones and other proteins, playing a key role in gene expression regulation and cancer cell proliferation. By inhibiting PRMT1, CTS2190 aims to disrupt oncogenic signaling pathways, making it a potential targeted therapy for various solid tumors. The drug is currently being evaluated in Phase 1/2 clinical trials for its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced or metastatic solid tumors—including non-small cell lung cancer (NSCLC), pancreatic cancer, and triple-negative breast cancer[1][2][5].
- Other names
- CTS 2190CTS2190CTS-2190
02
Targets
PRMT1 (Protein Arginine Methyltransferase 1)
Beyond the preview
Go deeper on CTS2190.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTS2190.